The Salbutamol Inhalation industry has seen notable shifts over the past 18 months, driven by strategic collaborations and regulatory updates. A key development was the partnership between Novartis and Propeller Health in 2023 to integrate digital tracking technology into salbutamol inhalers, enhancing patient adherence monitoring. Meanwhile, Teva Pharmaceutical Industries acquired Cipla’s North American respiratory portfolio in early 2024, strengthening its position in the generic bronchodilator market. Regulatory changes, such as the FDA’s 2023 guidelines on reducing CFC use in metered-dose inhalers, have accelerated the adoption of environmentally friendly alternatives, pushing manufacturers to innovate in dry powder and soft mist delivery systems. Consumer demand has also tilted toward prefilled, single-dose inhalers, with Boehringer Ingelheim launching its Salbutamol Soft Mist® variant in 2023, emphasizing ease of use for elderly patients. Funding in the sector has surged, with RespirTech Innovations securing $50M in Series B financing in 2024 to develop AI-powered inhalation devices. These trends underscore a Salbutamol Inhalation industry trends landscape prioritizing sustainability, digital integration, and patient-centric design.
